New York recalls

Wonton Specialist Inc. is recalling 16 oz packages of Lo Mein Noodle because they contain FD&C Red No. 40 (a food dye) that is not listed on the label. This can be a concern for people with allergies or sensitivities to this ingredient or those who avoid it for dietary or religious reasons.

Wonton Specialist Inc. noodles (12 oz and 5 lb packages) contain FD&C Red No. 40 food dye that is not listed on the label. This undeclared ingredient may pose a risk to people with allergies or sensitivities to the dye. About 550 bags are affected.

Wonton Specialist Inc. pan fried noodles in 16 oz and 5 lb bags contain FD&C Red No. 40, a food dye that is not declared on the label. This poses a risk to people with allergies or sensitivities to artificial dyes, and to those who avoid the ingredient for religious or personal reasons. About 500 bags were distributed in New York, New Jersey, and Pennsylvania.

Savor Seasonings LLC's bulk Organic Cheddar Type Seasoning tested positive for milk allergen that was not listed on the label. The affected product is packaged in 50-lb bags and distributed in Canada. This poses a serious risk to people with milk allergies.

The Hampton Grocer's Lacnola Small Batch Lactation Granola (8 oz pouches) may be contaminated with Salmonella. Two specific lot codes are affected: HGLC-102125 (expires 21 Oct 2026) and HGLC-021326 (expires 13 Feb 2027).

Prince Bakery Inc. is recalling Prince Sesame French Bread because sesame is not listed in the ingredient statement, even though the product name indicates it contains sesame. People with sesame allergies could have a serious reaction if they eat this bread without knowing sesame is present.

Prince Bakery Italian Bread labeled as containing sesame does not list sesame in its ingredient statement. People with sesame allergies relying on the ingredient list may not realize the product contains sesame, which they need to avoid.

Optimal Balance Pharmacy's Glutathione 200 mg/mL injectable solution failed quality testing and was found to contain bacterial endotoxin levels above safe limits. This contamination poses a risk of serious infection or systemic reaction when injected. The affected lot (LG342009076) was distributed nationwide.

Baxter Healthcare Corporation is recalling 0.9% Sodium Chloride Injection USP in 500 mL VIAFLEX plastic containers because some bags contain fiberglass particles. The affected lots are Y495523 and Y495523A, expiring October 31, 2027. No injuries have been reported.

Golden State Medical Supply Inc. is recalling one lot of Prasugrel HCI 10mg tablets because they failed to meet dissolution specifications—meaning the tablets may not break down properly in the body and release the medication as intended. This could affect how well the medication works. The recall affects lot #GS062298 with an expiration date of 09/30/2026.

American Health Packaging distributed buprenorphine sublingual tablets with incorrect labeling. The affected medication is a prescription opioid used to treat pain and opioid use disorder. A label mix-up could result in dosing errors if patients or healthcare providers rely on incorrect information.

Mylan Pharmaceuticals is recalling Prasugrel 10mg tablets (Lot #3225272, expiring September 30, 2026) because they failed dissolution testing during 18-month stability studies. This means the tablets may not break down and release the medication as intended in the body. No injuries have been reported.

Sage Products is recalling specific lots of 2% Chlorhexidine Gluconate non-sterile cloths due to potential cross-contamination with other products during manufacturing. The affected cloths may not meet safety and quality standards. No injuries have been reported.

Teva Pharmaceuticals discovered that some bottles of trazodone 50 mg tablets contain foreign tablets or capsules mixed in with the correct medication. The issue affects one lot (1394026) with an expiration date of February 2028. No injuries have been reported.

Supernus Pharmaceuticals is recalling one lot of Trokendi XR (topiramate) 50 mg extended-release capsules because the medication did not dissolve as designed. When a medication fails to dissolve properly, the body may not absorb the full dose, potentially reducing its effectiveness.

Mylan Pharmaceuticals is recalling specific lots of Mycophenolate Mofetil for injection (500 mg/vial) because the medication failed to meet dissolution specifications—meaning the drug may not dissolve properly in the body. This could affect how well the medicine works. The recall affects two lots distributed nationwide.

Testing by Allies Group found that certain batches of The ONE SPF 50 Invisible Sunscreen Gel may not provide the SPF 50 sun protection stated on the label. The affected product was distributed nationwide in the U.S. No injuries have been reported.

Testing found that Allies Group THE ONE SPF 50 Invisible Sunscreen Gel may not provide the advertised SPF 50 sun protection. The product was distributed nationwide in the U.S. The affected sunscreen was made in the U.S.A and distributed by Allies Group Pte Ltd.

Testing found that THE ONE SPF 50 Invisible Sunscreen Gel sachets may not provide the SPF 50 sun protection stated on the label. The affected product was distributed nationwide in the U.S. No injuries have been reported.

Testing by Allies Group Inc. found that The One SPF 50 Invisible Sunscreen Gel may not provide the full SPF 50 sun protection stated on the label. The affected product was distributed nationwide in the U.S. across multiple lot codes with expiration dates through June 2029.

Bionpharma Inc. is recalling Doxylamine Succinate and Pyridoxine HCl Delayed-Release tablets (10 mg/10 mg, 100-count bottles) because some bottles contain unidentified foreign tablets or capsules mixed in with the correct medication. The affected lot is DMA25006 with an expiration date of 11/30/2028. This issue was discovered during quality control.

Baxter Healthcare is recalling one lot of Daptomycin in 0.9% Sodium Chloride Injection due to deviations from current good manufacturing practice (CGMP) standards during production. The affected lot (NC193856, expiring 04/18/2028) was distributed nationwide, Puerto Rico, and Chile.

Baxter Healthcare Corporation is recalling one lot of Vancomycin Injection (NDC 0338-3583-01, Lot #NC193894) due to deviations from good manufacturing practices (CGMP). The affected lot was distributed nationwide in the US, Puerto Rico, and Chile.

Baxter Healthcare Corporation is recalling three lots of Vasopressin injection due to manufacturing process deviations that do not meet FDA quality standards. The affected lots were distributed nationwide, in Puerto Rico, and Chile. No injuries have been reported.

Baxter Healthcare Corporation is recalling one lot of Clindamycin Injection USP in 5% Dextrose due to deviations from manufacturing quality standards. The affected lot was distributed nationwide, in Puerto Rico, and Chile.

Baxter Healthcare Corporation is recalling one lot of Clindamycin Injection USP in 5% Dextrose (900 mg/50 mL) due to deviations from current good manufacturing practices (CGMP). The affected lot was distributed nationwide, in Puerto Rico, and Chile. No injuries have been reported.

Baxter Healthcare Corporation is recalling a specific lot of Clindamycin Phosphate in 0.9% Sodium Chloride Injection due to deviations from current Good Manufacturing Practice (CGMP) standards during production. The affected lot (NC193689, expiring 10/16/2027) was distributed nationwide, as well as to Puerto Rico and Chile.

Baxter Healthcare has recalled three specific lots of Clindamycin Injection USP (900 mg per 50 mL) due to deviations from Good Manufacturing Practice (CGMP) standards during production. The affected lots were distributed nationwide, Puerto Rico, and Chile. No injuries have been reported.

Baxter Healthcare has recalled multiple lots of Nexterone (amiodarone HCI) injection due to deviations from good manufacturing practices (CGMP) during production. The affected lots were distributed nationwide, Puerto Rico, and Chile. No injuries have been reported.

Baxter Healthcare has recalled specific lots of CARDENE IV (nicardipine hydrochloride) injection due to deviations from manufacturing quality standards. The affected lots were distributed in the United States, Puerto Rico, and Chile.